Facial Injectable Market - Databook 2025 to 2034

The global facial injectable market size was evaluated at USD 12.36 billion in 2024 and is expected to grow around USD 40.99 billion by 2034, registering a CAGR of 12.74% from 2025 to 2034.

Highlights of the Facial Injectable Market

• North America dominated the global market in 2024.
• Europe is projected to host the fastest-growing market in the coming years.
• By product, the botulinum toxin Type A segment made up the largest share of the facial injectables market in 2023.
• By product, the hyaluronic acid (HA) segment is expected to have the highest compound annual growth rate during the forecast period.
• By application, the aesthetics segment dominated the dental services market in 2024.
• By application, the therapeutic segment is expected to be the most opportunistic during the forecast period.
• By end-use, the specialty clinics segment dominated the market in 2023.
• By end-use, the spa & beauty segment is set to be most opportunistic during the forecast period between 2024 and 2033.
• By generation, the millennials segment underwent notable growth in the market during 2024.
• By generation, the Gen X segment is expected to emerge with notable growth during the forecast period.

Industry Valuation and Growth Rate Projection

The facial injectable market encompasses facial injectables, also called dermal fillers, soft tissue fillers, lip and facial fillers, or wrinkle fillers are FDA-approved medical substances injected into the skin to enrich the facial exterior. Injectables are a popular nonsurgical cosmetic procedure that can help generate a charming and more sprightly appearance. Dermal fillers can be used for flattening wrinkles and lines, reestablishing facial volume, and modifying facial abnormalities and scars. Both men and women are popularly reaching out to modify their facial appearances to achieve a wrinkle and line-free look. Men, although low in numbers, are largely using facial injectables.

• According to a survey by McKinsey in 2021, 5% of the total dermal filler and biostimulator users were men in 2018, and the figure rose to 7% in 2021. 

Facial Injectable Market: Stats and Figures

• In 2020, approximately 1.3 million soft tissue filler (STF) treatments were executed by plastic surgeons in the United States, and the revenue generated was around $1 billion.
• In 2021, as per McKinsey’s research, the global aesthetics injectables market is expected to grow 14% per annum globally in the next five years.
• In 2023, South Korea caught the fancy of 605,768 non-resident foreign patients for cosmetic surgeries, as stated by the Ministry of Health and Welfare, involving the most people coming from Japan, China, the United States, and Thailand.
• Among the most conventional non-surgical cosmetic procedures internationally, injections of botulinum toxin and dermal fillers have established their place, while probably taking the market growth ahead by 15.4% until the year 2030.

Industry Leader Announcements

• Jeff Bedard, Founder and Chief Executive Officer at Crown Laboratories, Inc:

While speaking of doing good to the skincare industry as a whole, Bedard said, “We are excited to officially welcome Revance to the Crown family. This acquisition strengthens our leadership position and enhances our ability to deliver innovative solutions to customers, with what we believe is a comprehensive portfolio that represents the three pillars of facial aesthetics – relax, restore, and regenerate – and we will support these offerings with a highly trained and experienced sales force. We are well-positioned to become a global leader in the aesthetics and skincare industry and will leverage our combined resources to create long-term value for our stakeholders.”

How AI Has Benefitted the Market

• The facial injectable market, alongside AI, can commence to be very helpful for facial injectable treatments and other fields of dermatology. Here’s how AI operates with the dermal fillers:
• Automated injectors: AI-driven robotic injectors can accomplish subtle injections with high precision, most importantly keeping in mind the safety of individuals.
• Detecting anomalies: AI algorithms can make the analysis procedure automatic to find or identify potential complications, like tissue reactions, initially, to keep the patients secure.
• 3D facial shaping: When it comes to a patient’s face, AI can structure 3D models with accuracy. This helps the doctors to know how much filler is required.
• Real-time feedback: Using a digital marker, an AI tool, with live video streaming of a patient’s face, dermatologists can study the exact injection points to perform treatments confidently while reducing latent risks.

Geographical Insights 

The global facial injectable market is experiencing significant growth, with North America maintaining its position as the dominant region while Europe emerges as a swiftly growing market. The APAC region is likely to thrive at a faster pace.

North America

The North American market held a prevailing share in light of the FDA passing approval and is looking forward to approving the application of companies, particularly in the United States.

Novaestiq Corp.’s partner, Croma-Pharma GmbH, confirmed the proposal of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the saypha® MagIQ™ hyaluronic acid dermal filler.

Europe

The European market can be seen flourishing as a consequence of the introduction of its state-of-the-art technologies in countries outside the region.

CollPlant Biotechnologies declared the enlargement of its distribution channels for its Vergenix™ STR product in Europe and Asia, and the company is eagerly awaiting the expansion of its distribution network for Vergenix STR to other regions.

APAC

The facial injectable market in the APAC is poised to grow in the forecast period, given that countries like India, South Korea, and China are contributing to the development of novel technologies in facial aesthetics.

Advanced Aesthetic Technologies, Inc. ("AAT") proclaimed that their partner Lanzhou Biotechnique Development Co., Ltd., in China, has gained approval to promote sales of their unique dermal filler Algeness® VL agarose facial injection filler, a 2.5% agarose gel dermal filler.

Recent Developments:

• In 2025, Crown Laboratories procured Revance Therapeutics with the purpose of providing world-class solutions regarding facial injectables to the customers as well as the stakeholders.
• In 2025, as Prollenium publicizes its launch of PACE Academy (Prollenium Advanced Clinical Education), enthusiastic about advanced training and education in medical aesthetics, it forms a collaboration with Harley Academy, which is a leading company in higher education for aesthetic medicine.

Competitive Landscape 

The facial injectable market is highly competitive, with leading healthcare companies such as Medytox Inc., AbbVie Inc., Galderma Group AG, Revance Therapeutics, Bioxis Pharmaceuticals, BIOPLUS CO., LTD., Merz Pharma, Ipsen Pharma, and Johnson & Johnson holding the highest market share. Emerging biotech firms also play a fundamental role by fostering a dynamic and evolving competitive landscape.

The market is dominated by several healthcare companies prominent for their significant contributions to enhancing cosmetic treatment in the injectable industry. Based on recent data, the top three leading companies are:

• Company Name: Medytox Inc.
• Year of Incorporation: 2000
• Headquarters: Cheongju-si, South Korea

The yearly revenue of Medytox Inc. was positioned at $228,621,969 in 2024.

• Company Name: AbbVie Inc.
• Year of Incorporation: 2012
• Headquarters: Illinois, United States

The gross profit of AbbVie Inc. soared from $33,903,000 in 2023 to $39,430,000 in 2024.

• Company Name: Galderma Group AG
• Year of Incorporation: 1981
• Headquarters: Zug, Switzerland

The annual revenue of Galderma Group AG was $4,440,000 in 2024.